Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
Titel:
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
Auteur:
Wang, Eunice S Issa, Ghayas C Erba, Harry P Altman, Jessica K Montesinos, Pau DeBotton, Stephane Walter, Roland B Pettit, Kristen Savona, Michael R Shah, Mithun Vinod Kremyanskaya, Marina Baer, Maria R Foran, James M Schiller, Gary Adès, Lionel Heiblig, Mael Berthon, Celine Peterlin, Pierre Rodríguez-Arbolí, Eduardo Salamero, Olga Patnaik, Mrinal M Papayannidis, Cristina Grembecka, Jolanta Cierpicki, Tomasz Clegg, Bradley Ray, Joshua Linhares, Brian M Nie, Kun Mitra, Amitava Ahsan, Julie Mackey Tabachri, Marilyn Soifer, Harris S Corum, Daniel Leoni, Mollie Dale, Stephen Fathi, Amir T